🤓 Just 1 week into 2025: These 7 AI-picked stocks are up 9%+ eachUnlock Stocks

BRIEF-Moberg Pharma gets approval to start phase 3 study for MOB-015 in N. America

Published 2016-08-10, 02:41 a/m
© Reuters.  BRIEF-Moberg Pharma gets approval to start phase 3 study for MOB-015 in N. America

© Reuters. BRIEF-Moberg Pharma gets approval to start phase 3 study for MOB-015 in N. America

MBPH
-1.31%

Aug 10 (Reuters) - Moberg Pharma Ab MBPH.ST :

* Says announces approvals to start phase 3 study for MOB-015 in U.S. and Canada Link to press release: http://mb.cision.com/Main/1662/2056697/547647.pdf Further company coverage: MBPH.ST

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads.

Should you invest $2,000 in MBPH right now?

With MBPH making headlines, savvy investors are asking: Is it truly valued fairly? In a market full of overpriced darlings, identifying true value can be challenging. InvestingPro's advanced AI algorithms have analyzed MBPH alongside thousands of other stocks to uncover hidden gems. These undervalued stocks, potentially including MBPH, could offer substantial returns as the market corrects. In 2024 alone, our AI identified several undervalued stocks that later surged by 30 or more. Is MBPH poised for similar growth? Don't miss the opportunity to find out.

Reveal Undervalued Stocks Now

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.